Yet the stock (BMY) was up about 6% on Wednesday after the drug giant announced the delay. In its statement, the company said it now expects to share the data from the Phase 3 trial sometime next year ...

Bristol Myers Squibb is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s ...

Bristol Myers will enroll more patients in its Cobenfy Alzheimer's psychosis study after site irregularities, with ...

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

For individuals diagnosed with Alzheimer’s disease or acting as the caretaker for someone with Alzheimer’s, support and ...

How much physical activity—and how often—is needed to help stall dementia? For older adults with mild cognitive decline, there is now an answer: at least 20 minutes, at least twice weekly.

Bristol-Myers Squibb shares rallied Wednesday after the drugmaker delayed the release of eagerly awaited clinical-trial results for a potential Alzheimer’s disease treatment. Analysts said investors ...

After Bristol Myers (BMY) announced this morning that the ADEPT-2 study of Cobenfy in in Alzheimer’s disease psychosis will continue enrolling ...

Trontinemab, designed to reach the brain better than gantenerumab, led to amyloid negativity in 92 percent of patients at the ...

The phase 3 comeback story that Bristol Myers Squibb investors were eagerly anticipating is not to be—at least not this year.

Certain amounts of hydrogen sulfide can help protect aging brains from Alzheimer’s disease, according to a 2021 study ...

Researchers at the Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC have identified a previously unknown pattern of organization in one ...